Format

Send to

Choose Destination
J Biomed Sci. 2000 Jul-Aug;7(4):292-8.

Inhibition of ras oncogene: a novel approach to antineoplastic therapy.

Author information

1
Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Argentina. ogs@citynet.net.ar

Abstract

The most frequently detected oncogene alterations, both in animal and human cancers, are the mutations in the ras oncogene family. These oncogenes are mutated or overexpressed in many human tumors, with a high incidence in tumors of the pancreas, thyroid, colon, lung and certain types of leukemia. Ras is a small guanine nucleotide binding protein that transduces biological information from the cell surface to cytoplasmic components within cells. The signal is transduced to the cell nucleus through second messengers, and it ultimately induces cell division. Oncogenic forms of p21(ras) lead to unregulated, sustained signaling through downstream effectors. The ras family of oncogenes is involved in the development of both primary tumors and metastases making it a good therapeutic target. Several therapeutic approaches to cancer have been developed pointing to reducing the altered gene product or to eliminating its biological function: (1) gene therapy with ribozymes, which are able to break down specific RNA sequences, or with antisense oligonucleotides, (2) immunotherapy through passive or active immunization protocols, and (3) inhibition of p21(ras) farnesylation either by inhibition of farnesyl transferase or synthesis inhibition of farnesyl moieties.

PMID:
10895051
DOI:
10.1007/bf02253247
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center